Printer Friendly

NEW AIDS DRUG STUDY ANNOUNCED; STANFORD RESEARCHERS TO STUDY THYMOSIN alpha I

 BETHESDA, Md., Dec. 18 /PRNewswire/ -- Alpha 1 Biomedicals (NASDAQ: ALBM) today announced a new trial of Thymosin alpha 1 combined with Zidovudine (AZT) and Polyethelene Glycol Modified Interleukin-2 (PEG-IL-2) in the treatment of people with AIDS whose CD4 cell count is between 100 and 200. The drug combination is being studied as a means of increasing the levels of circulating lymphocytes in order to help AIDS patients fight opportunistic infections and prevent the development of cancer.
 The new pilot study, which has already enrolled a small group of patients, is supervised by Thomas C. Merigan Jr., M.D., Becker Professor of Medicine at Stanford. The study has three primary objectives.
 1) To assess the safety of this combination;
 2) To determine the acute and chronic ability of the combination to enhance CD4 and T-cell counts; and
 3) To determine the effect of the combination on certain HIV-1 virologic parameters.
 Preliminary findings of a study with various combinations of Thymosin alpha 1, alpha interferon and AZT were reported by Dr. Enrico Garaci, University of Rome, Italy, at the International AIDS Conference in Amsterdam last July. In patients treated over a period of 12-18 months, Dr. Garaci found a statistically significant increase in CD4 cell count primarily in patients on the triple therapy as opposed to either monotherapy or treatment with any combination of two of the three drugs. The Thymosin alpha 1 used by Dr. Garaci was manufactured by Alpha 1 Biomedicals using a proprietary chemical synthesis process and supplied to him by Sclavo SpA, a licensee of the company.
 Thymosin alpha 1, a naturally occurring peptide hormone with immunoregulartory properties, is also currently in a Phase II multicenter trial for the treatment of chronic hepatitis B.
 Alpha 1 Biomedicals, Inc. is a Bethesda-based biotechnology company engaged in the development of pharmaceutical products for the treatment of human immune disorders.
 -0- 12/18/92
 /CONTACT: Judith A. Hautala, Ph.D., vice president-corporate development of Alpha 1 Biomedicals, 301-564-4400; or Anita Monteith Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals/
 (ALBM)


CO: Alpha 1 Biomedicals ST: Maryland IN: MTC SU:

LR-SH -- NY014 -- 8107 12/18/92 10:08 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 18, 1992
Words:359
Previous Article:EXTENSION CORDS PRESENT POSSIBLE SHOCK HAZARD
Next Article:BUNKER HILL INCOME SECURITIES, INC. BOARD APPROVES PLAN OF REORGANIZATION FOR THE CLOSED END FUND
Topics:


Related Articles
THYMOSIN ALPHA 1 TO BE EVALUATED IN CLINICAL TRIAL IN MEXICO
SCICLONE PHARMACEUTICALS ANNOUNCES APPROVAL TO BEGIN CLINICAL TRIALS IN JAPAN FOR THYMOSIN ALPHA 1
PITT MEDICAL CENTER TO TEST NEW DRUGIN PATIENTS WITH HEPATITIS B AND CIRRHOSIS
THYMOSIN ALPHA 1 COMBINATION STUDY SUGGESTS CD4+ RESPONSE
NOVEL ACTIN-SEQUESTERING PEPTIDE TO BE DEVELOPED BY ALPHA 1 BIOMEDICALS, INC.
SIGNIFICANT RESULTS IN HEPATITIS C STUDY WITH THYMOSIN ALPHA 1 AND INTERFERON ALPHA COMBINATION THERAPY
SCICLONE PHARMACEUTICALS REPORTS CONTINUED ENCOURAGING TREND IN TAIWAN CLINICAL TRIAL AND COMPLETION OF ANALYSIS OF U.S. CLINICAL TRIAL
Hepatology Article Points to Promise of Thymosin Alpha 1 as a Therapy for Hepatitis C
SciClone's ZADAXIN(R) Thymosin Alpha 1 Decreases Formation of Lung Tumors In Mice

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters